Bectumomab (marketed under the trade name LymphoScan®) is a mouse monoclonal antibody and which it's used to treat non-Hodgkin's lymphoma. It has a radioisotope, technetium (99m TC) which it's added.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Bectumomab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Bectumomab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Bectumomab. |
| Estrone | Estrone may increase the thrombogenic activities of Bectumomab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Bectumomab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Bectumomab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Bectumomab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Bectumomab. |
| Estriol | Estriol may increase the thrombogenic activities of Bectumomab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Bectumomab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Bectumomab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Bectumomab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Bectumomab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Bectumomab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bectumomab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Bectumomab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Bectumomab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Bectumomab. |
| Equol | Equol may increase the thrombogenic activities of Bectumomab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Bectumomab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Bectumomab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Bectumomab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Bectumomab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Bectumomab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Bectumomab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Bectumomab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Bectumomab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Bectumomab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Bectumomab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Bectumomab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Bectumomab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bectumomab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Bectumomab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Bectumomab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Bectumomab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bectumomab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bectumomab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Bectumomab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Bectumomab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Bectumomab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Bectumomab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Bectumomab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bectumomab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bectumomab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Bectumomab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bectumomab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bectumomab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Bectumomab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bectumomab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Bectumomab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Bectumomab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Bectumomab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bectumomab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bectumomab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Bectumomab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Bectumomab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Bectumomab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Bectumomab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Bectumomab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Bectumomab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Bectumomab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Oregovomab. |
| IGN311 | The risk or severity of adverse effects can be increased when Bectumomab is combined with IGN311. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Adecatumumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Labetuzumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Matuzumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Fontolizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Bavituximab. |
| CR002 | The risk or severity of adverse effects can be increased when Bectumomab is combined with CR002. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Rozrolimupab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Girentuximab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Obiltoxaximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when Bectumomab is combined with XTL-001. |
| NAV 1800 | The risk or severity of adverse effects can be increased when Bectumomab is combined with NAV 1800. |
| Briakinumab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Briakinumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Otelixizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when Bectumomab is combined with AMG 108. |
| Iratumumab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Iratumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Enokizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Ramucirumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Farletuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Veltuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Ustekinumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Bectumomab is combined with Trastuzumab emtansine. |
| PRO-542 | The risk or severity of adverse effects can be increased when Bectumomab is combined with PRO-542. |
| TNX-901 | The risk or severity of adverse effects can be increased when Bectumomab is combined with TNX-901. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Bectumomab is combined with Inotuzumab ozogamicin. |
| RI 624 | The risk or severity of adverse effects can be increased when Bectumomab is combined with RI 624. |
| Stamulumab | The risk or severity of adverse effects can be increased when Bectumomab is combined with MYO-029. |
| CT-011 | The risk or severity of adverse effects can be increased when Bectumomab is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Bectumomab is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when Bectumomab is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when Bectumomab is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when Bectumomab is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Canakinumab. |